IMS 4112 and VLP of HBV as Th1 Adjuvants for a Recombinant Protein of HIV-1
<p><strong>Background:</strong> Current thinking suggests that vaccination approaches against the HIV-1should be directed to elicit a Th1 cell-mediated immunity, neutralizing antibodies and/or ADCC mediating antibody responses. Also, experimental evidences suggest that both the sys...
Saved in:
Main Authors: | Ingrid Rodríguez-Alonso (Author), Daymir García (Author), Emma Brown (Author), Stephane Ascarateil (Author), Enrique Iglesias (Author) |
---|---|
Format: | Book |
Published: |
Journal of Vaccines and Immunology - Peertechz Publications,
2016-12-17.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP
by: Sarah M. Valencia, et al.
Published: (2021) -
RNA Phage VLP-Based Vaccine Platforms
by: David S. Peabody, et al.
Published: (2021) -
Zika virus-like particle (VLP) based vaccine.
by: Hélène Boigard, et al.
Published: (2017) -
Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent
by: In Yong Bae, et al.
Published: (2020) -
A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine
by: Mohammad Nasir Uddin, et al.
Published: (2019)